Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Started at 10
Might not be anything to leak. I expect all items on the proxy to be approved. Might not see the PR until after hours.
Unless you are referring to Nasdaq listing news....
Whatever you say Sid. Won't be long before we know.
LOL exactly!!! Sometimes I just shake my head at things posted here.
I think the plan will soon be playing out in a positive way. I have expressed my view on the timing issues so I won't rehash it again. Looking forward to the next chapter in the AMBS, titled Nasdaq. I think the chapter begins in the next two weeks.
No worries GOducks, I understand what you are getting at. Once on the Nasdaq there won't be the OTC style dilution with institutional buy-in. Institutions will buy as part of the Shelf Offering. The shares issued to institutions will not be coming to market every 6 months like the current financing deals thus there won't be nearly the constant selling pressure we seeing now. If AMBS can lock in $20 million from institutions it will fund operations for more than a year. Many value creating milestones will be accomplished in that time frame.
I have been here for 2 years and 8 months so no need for a history lesson. I also studying technical analysis so I am acutely aware of how the chart reads. The Nasdaq and institutions are the only cure to the current situation.
Right, but in order to achieve that AMBS must continue to advance the science or there is no incentive for institutions to buy in.
It does appear to be building a base here. I would think the company has been holding because of or held back by the quorum issue. Once behind us I suspect there will be a steady streams of news over the next few months. I expect the news to include updates on Lympro sales/agreements, Lympro & MSPrecise CLIA timelines, ESS updates out of the Rutgers/Army Institute collaboration and the MANF Symposium (ODD for RAO approval?). Certainly any of those could spur some much needed institutional interest.
When one talks of a RS with only 13.3 million OS it's tough to be taken seriously, hence the number of followers.
Then to make further statements of a possible RS of 5:1 or 10:1 from a 36 million OS count....LOL. That would drop the OS to 7.2 or 3.6 million. Sure doesn't sound like a logical share structure.
Please show me where I said I was or was not confident in their research....
I simply pointed out that this research firm provided detailed information on how they came up with their price target. Unlike most that post here with general negative comments that could be said about many stocks.
Who said I was confident in their PPS target? Not I, I simply pointed out someone who gave in in depth report based on actual research. One other firm has a $18 PPS target.
No desire to check seethruequity's track record as my timeline is years down the road, not 12 months. But feel free to research their track record and report back. My only point, which still stands, is that anyone can make general negative statements on a message board with no specifics to back up their claims.
Agee 100%. The DOD will see results right away from ESS and spur them to provide additional funding. As many in the burn community have said its a tragedy that ESS hasn't made it to market yet.
It's really easy to come on a message board and calls someone else's 17 page reports BS while providing little to dispute there 12 month price target except for a short term drop in pps.
Surely there will be no value in AMBS in 6 months with just these couple things going on:
-LymPro and MSPrecise both CLIA approved
-ESS Phase 2 results coming in periodically from their teaming with Rutgers and the Army Institute
I could list more but why bother. Anyone truly following along knows where mid/long term value is coming from...and it's not from a message board.
Next leg up starts next week, see you at $45 a share next year according to this equity firm:
http://finance.yahoo.com/news/seethruequity-initiates-coverage-amarantus-bioscience-130000691.html
Or you could listen to random folks on a message board... lol
This was stated in the July 22 press release:
"This additional validation demonstrated for LymPro raises the importance for its potential use in biomarker-supported selection of Alzheimer's disease patients for clinical trials. It has the convenience of being a blood test while reflecting the same type of cell cycle reentry dysfunction found in the brains of these patients," said Paula T. Trzepacz, M.D., Clinical Professor of Psychiatry at Indiana University School of Medicine and member of the Amarantus Clinical Advisory Board. "LymPro has the potential to become one of the fundamental diagnostic tools in Alzheimer's drug development, and we look forward to adding FDA-approved PET imaging agents to further validate LymPro vis-a-vis diagnostic gold standards."
LymPro is now being compared head to head with the gold standard test, PET. LymPro should also be CLIA certified by the end of the year. Unfortunately sales of LymPro to RUO market hinge on when trails are starting and how the trail is testing for ALZ.
GC stated during the SHM in August 3rd that we would be hearing much more on MSPrecise over the coming month.
So you are referring to immediate value. In bio-techs value is created over time, by advancing the science. All in good time.
You said:
"If you look at the history of when he has said such words, nothing of significance happened at least that increased shareholder value."
That is not true, unless you are saying that advancing the science doesn't increase shareholder value.
Indeed September is shaping up to be a busy month, thanks for sharing this info.
I expect a steady follow of news once the vote is behind us next Wednesday. Looking for MSPrecise to start getting much more attention in the coming months.
The pipeline has matured significantly over the past year and that will soon reflect in the PPS.
September 2nd, Wednesday. Then we will hear shortly thereafter about the NasDaq uplisting.
to your pointw.
1. only a novice would think those people don't matter. you are only as good as the people you surround yourself with
JN worked for Zacks so not sure what he has to do with anything
2. all in good time
3. you are talking about something that hasnt happened yet to make up what will happen after that.....i need to borrow your crystal ball
The products are so bad that's way the company has attracted big names to there BOD, BOA and SAB's. Give me a break!
LymPro results have been so bad that its being compared against PET, current gold standard test. Obviously you don't test a failing diagnostic test against the gold standard unless the results are good.
How exactly would another RS work with only 13 million OS?
Your information isn't even logical or pointing to anything specific.
Talking with GC post meeting he is definitely concerned about the constant slide of the share price. Those saying he doesn't care weren't there to look the man in the face and listen to him talk.
One thing you need to remember, MANF is his fathers life work and what this company was founded on. Do you really think he doesn't care if the company fails and his fathers life work has to be sold for pennies on the dollar? GC understands he needs to get to the NASDAQ in order to succeed. The company needs institutional buy-in which only happens on the big boards, not the OTC.
With Phase 2 trials and ODD's it's pretty hard to believe institutions won't buy in given the opportunity. Given the companies BOD, BOA and SAB's they are very well connected and likely have intuitional interest already as GC has stated.
Tune out the noise here!! Remember there are really only three types of people here longs(swing traders), shorts and investors. The stock market is no place for emotions!!! Have your own plan and stick with it. If you are here for the science then nothing has changed except the timeline.
I'm aware it was a SA article. This is old news about JN, it happened weeks ago. JN responded to someone back then so probably won't repeat himself to someone who hasn't been following closely.
It's because he doesn't work for Zacks anymore.
Great post redspeed. The Nasdaq listing will change the landscape here.
No, I was only taking the therapeutics side.
GC for president... lol
Go AMBS
I guess that makes you closer than most here. Kinda why I don't make predictions.
It's only money and hope you didn't invest more than you can afford to lose.
To date the science hasn't failed and until it does I will hang tight. ESS works without question.
ESS will ensure MANF gets to the clinic. But paint the picture as ugly as you want, it doesn't mean that the story you paint is true.
Yep, the institutions taking positions once on the NASDAQ will like the list of patents held by AMBS.
You only needed a .05 drop today to be right...but couldn't quite get there. Predictions are tough, maybe tomorrow.
Up side potential is much greater, IMO.
I believe it has to be after, but very soon after.
I have an idea of when AMBS will uplist. If you don't then maybe you should follow more closely and quit worrying about elephants.
It won't be long before the Army Institute and Rutgers are talking more about ESS. Institutions won't be listening to just GC.
The difference is big financial institutes invest in NASDAQ companies based on the science. That investment is made looking at longer term prospects, which AMBS has lots of. On the OTC the Dominions of the world finance because they can make a buck buy dumping their shares into the market hoping to push the PPS down so they can get more shares the next time the company needs money.
Why do you think some post the silly fact that pre-revenue biotechs need money day after lately? Because they know once on the NASDAQ the landscape changes. But certainly being on the NASDAQ guarantees nothing except greater possibilities that don't exist on the OTC.
Your entire negative sediment seems to revolve around GC, you talk nothing about the science. The bottom line for me is that the science has advance significantly over the past year with many key milestone occurring in the next 3 to 9 months.
I agree with what you said and it would be great to see some non-dilutive financing but it just hasn't happened . GC stated at the SHM in NYC that the company has been passed over do to being on the OTC with no major financial backing.
I am only speculating on the $20 million in financing but the shelf offering is in place to raise up to $150 million. I think the SP will get a boost once on the NASDAQ. I also expect after the uplist institutions will be buying in over the next few months. That should significantly reduce the selling presssure.
I truly believe GC would much rather sell the diagnostics division outright. I think that is why they want CLIA cert. for both LymPro and MSPrecise. And as they raise funds through the shelf offering it will allow them to close on the Georgetown assay. With those things done the diagnostics division is worth 5 times the current market cap.
Look, I haven't forgot the past but the bottom line is things have been said that haven't work out or played out. Rather than focus on the past I focus on the future. The cost of closing the ESS deal has pushed the PPS down however it will also push the PPS higher than it ever has. ESS is huge, make no mistakes.
I meet GC for the first time in NYC at the SHM. He spoke with two other investors and myself for about 15 minutes after the meeting. Say what you want but i have a different opinion from what I heard heard and saw first hand.
I will not support that and also have said nothing about this being bad luck. This is not how I saw this playing out however the company, with the uplisting, is positioned to make a major move in my opinion. Bringing ESS on will turn out to be a genus move and will likely bring in enough money to get MANF to market. And getting MANF to market has always been the primary goal.
I am looking forward, not backward.
Not worried. And sounds like you are waiting for that so take care, see you in January. Certainly no reason for you to hang around here.
If the company needs to double the OS to raise the 20 million I am all for it. Why....well because the alternatives are much much worse! And in raising 20 million the company will move its pipeline ahead a tons which will very likely put the market cap in the 200 million plus range. The current market cap is crazy low and even you admit this.
You can continue to focus on the past and be pissed off every day or you can focus on where the company is going. Yes every investor would like to see the PPS much higher, that includes GC. However it hasn't worked out that way but with the NASDAQ uplist things can improved quickly.